|
AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization
|
16 February 2021 |
|
AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity
|
10 February 2021 |
|
COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials
|
03 February 2021 |
|
COVID-19 Vaccine AstraZeneca recommended for use in the EU
|
29 January 2021 |
|
Serum Institute of India obtains emergency use authorisation in India for AstraZeneca's COVID-19 vaccine
|
06 January 2021 |
|
AstraZeneca's COVID-19 vaccine authorised for emergency supply in the UK
|
30 December 2020 |
|
AZD1222 Oxford Phase III trials interim analysis results published in The Lancet
|
08 December 2020 |
|
AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
|
23 November 2020 |
|
FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial
|
24 October 2020 |
|
COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials
|
09 October 2020 |